Deep dive into CSL, NUF & IPH and charts on China risks
Fund Manager Chris Pedersen looks at CSL (ASX:CSL), Nufarm (ASX:NUF), IPH (ASX:IPH) and charts on China risks.
Read More
Csl Limited
Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
Spotlight Videos
Deep dive into CSL, NUF & IPH and charts on China risks
Fund Manager Chris Pedersen looks at CSL (ASX:CSL), Nufarm (ASX:NUF), IPH (ASX:IPH) and charts on China risks.
WATCH VIDEOAll Csl Limited Content
News
Heated audience at CSL’s AGM
CSL's (ASX:CSL) Annual General Meeting in Melbourne on Wednesday turned into a heated discussion regarding executive pay and a declining share price, casting a shadow over the reaffirmation of guidance for the upcoming year.
Read More
Shareholders to receive more from CSL as revenue and earnings surge
Shareholders of the blood products giant CSL (ASX:ASX) are set to benefit as the company increased its revenue and earnings in the year leading up to June 30.
Read More
Market Smells Blood, Gives CSL a Whack
Shares in pharma giant CSL took a hit yesterday after it revealed a larger than forecast loss from currency movements for its FY2022-23.
Read More
Airlie FM April 2023 Quarterly Update
Airlie FM's Emma Fisher provides her views on the current market environment and discusses her recent trip to Europe where she visited the HQs of key holdings CSL and QBE Insurance.
Read More
Analyst Views
CSL – Macquarie rates the stock as Outperform
The Outperform rating and target price of $312.00 are retained.
Read More
CSL – Macquarie rates the stock as Outperform
The broker retains an Outperform rating and lowers the target to $312.00 from $327.25.
Read More
CSL – Morgans rates the stock as Add
Add rating retained. Target price eases to $327.60 from $334.70.
Read More
CSL – Morgans rates the stock as Add
Add rating is maintained. Target price rises to $334.7 from $324.4.
Read More
CSL – Credit Suisse rates the stock as Neutral
The $315 target and Neutral rating are unchanged.
Read More
